Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).
introduction
The epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab improves overall survival when added to standard chemotherapy used in the treatment of metastatic colorectal cancer (mCRC) [1] , non-small-cell lung cancer [2] , recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) [3] and when combined with radiotherapy in the treatment of locally advanced SCCHN [4] . The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study demonstrated that the tumor mutation status of codons 12 and 13 of the KRAS gene was predictive for the activity of cetuximab combined with oxaliplatin plus infusional 5-fluorouracil (5-FU) and folinic acid (FOLFOX-4) in the firstline treatment of mCRC [5] .
The OPUS study therefore confirmed earlier retrospective investigations of single-arm trials [6] [7] [8] [9] , which indicated that cetuximab activity was limited to patients whose tumors were KRAS wild type. It was also consistent with retrospective analyses in other randomized studies in mCRC involving cetuximab administered as monotherapy in patients who had failed prior chemotherapy [10] and as first-line treatment in combination with irinotecan and infusional 5-FU/folinic acid (FOLFIRI) [11] . These analyses demonstrated improved outcome for patients with KRAS wild-type mCRC who received treatment including cetuximab, with overall survival improved in both studies in the cetuximab arm compared with the control arm [1, 10] . Retrospective analyses of several small studies also suggested that the tumor mutation status of original article a second gene, BRAF, the product of which is a downstream effector of KRAS in the MAPK pathway [12] , may be predictive and/or prognostic in mCRC patients receiving EGFR monoclonal antibody treatment [13] [14] [15] [16] [17] . This raised the possibility that consideration of the tumor BRAF mutational status in patients with KRAS wild-type disease might allow the further tailoring of cetuximab treatment. At the time of initial reporting, overall survival data were not available for the OPUS study [5] . In addition, KRAS tumor mutation data were only available for 69% of patients in the intention-to-treat (ITT) population. Although comparison of the baseline characteristics and efficacy data suggested that the KRAS population was essentially representative of the ITT population, it was believed that the accuracy and strength of the conclusions would be increased if tumor KRAS mutation status could be determined for a higher proportion of patient samples. The current manuscript therefore reports an updated analysis based on the consideration of overall survival and other end points in an increased population of patients for which tumor KRAS mutation status has been determined.
patients and methods

key eligibility criteria
Eligibility criteria have previously been described [5] . The study was carried out in accordance with the Declaration of Helsinki. All patients provided written informed consent for the initial clinical study.
study design and treatment
As reported [5] , patients were randomly assigned to receive FOLFOX-4 (oxaliplatin 85 mg/m /week thereafter), until the occurrence of progressive disease or unacceptable toxicity, as first-line treatment for mCRC. Response was assessed radiologically, every 8 weeks.
The primary end point was response, as evaluated by an independent review committee according to modified World Health Organization criteria. Secondary end points included progression-free survival (PFS), overall survival and safety. Retrospective subgroup analyses investigated associations between study end points and KRAS and BRAF tumor mutation status.
KRAS and BRAF mutation analysis DNA was extracted from formaldehyde-fixed paraffin-embedded (FFPE) tumor tissue and from tissue recovered from stained slides previously used to evaluate tumor EGFR expression. The mutation status of codons 12 and 13 of exon 2 of the KRAS gene was assessed using a PCR clamping and melting curve technique, as previously described [5] . BRAF mutation status (V600E) was analyzed using a similar approach (BRAF V600E kit; TIB MOLBIOL, Berlin, Germany).
statistical methods and considerations
The primary efficacy analysis was carried out on the ITT population [5] . The prespecified analyses for the ITT population were repeated by KRAS mutation status in those ITT patients whose tumors were available and provided an evaluable DNA sample (KRAS population). With a new clinical cut-off date of 30 November 2008 and a new biomarker cut-off date of 12 August 2009, this updated retrospective analysis comparatively investigated efficacy in patient subgroups defined according to KRAS and BRAF tumor mutation status. For tumor response, treatment groups were compared using a stratified Cochran-Mantel-Haenszel (CMH) test. PFS and overall survival times were analyzed by the Kaplan-Meier method [18] and stratified logrank test. The presented efficacy analyses were of an exploratory nature and P values were therefore not adjusted for the multiplicity of statistical tests. Further exploratory analyses of baseline variables of potential prognostic value were carried out in subgroups of those patients with KRAS wild-type tumors. Hazard and odds ratios are presented within the different patient populations for cetuximab plus FOLFOX-4 versus FOLFOX-4 alone or KRAS wild type versus mutant. Multivariate regression analyses of best overall response (logistic regression model), PFS and overall survival (Cox regression models) were conducted to explore whether the treatment effect varied significantly according to tumor KRAS mutation status in order to evaluate its predictive utility in this study.
Adverse events (AEs) occurring up to 30 days after the end of the last administration of study treatment were analyzed using the Medical Dictionary for Regulatory Activities (MedDRA) version 10.0, with special emphasis on grade 3 and 4 toxic effects according to the National Cancer Institute-Common Toxicity Criteria, version 2.0. Cardiac events were evaluated by compiling specific Maintenance and Support Services Organization, Chantilly, Virginia preferred terms of related medical concepts, including arrhythmia, congestive heart failure, infarctionischemia and sudden death (see supplemental Methods, available at Annals of Oncology online for full list).
results
patients and samples
The OPUS ITT population comprised 337 eligible, randomly assigned and treated patients: 169 receiving cetuximab plus FOLFOX-4 and 168 receiving FOLFOX-4 alone. The safety population (n = 338) included one additional patient who was erroneously randomized in the interactive voice-response system and was consequently excluded from the ITT population. Subsequent to the initial published analysis, the number of patients in the KRAS population was increased from 233 (69%) to 315 (93%) through the use of tumor DNA extracted from FFPE slide-mounted tissue sections previously used for the immunohistochemical evaluation of EGFR expression. The baseline characteristics according to the treatment arm of the expanded KRAS population matched closely those of the ITT population (Table 1) . BRAF mutation status (V600E) was evaluable in tumor DNA samples from 309 of 315 patients in the KRAS population.
treatment compliance
Exposure to cetuximab was similar in the ITT and KRAS populations, with 84% and 85% of patients, respectively, having a relative dose intensity (RDI) of ‡80% ( Table 2) . RDIs for oxaliplatin and 5-FU were also comparable between the treatment arms of the ITT and KRAS populations of patients. In the KRAS population, exposure to cetuximab was similar for patients whose tumors were KRAS wild type and mutant, with 79% and 91% of patients, respectively, achieving an RDI of ‡80%. RDIs for oxaliplatin and 5-FU were also comparable between the treatment arms for patients whose tumors were KRAS wild type and KRAS mutant and were similar for patients with or without mutation, according to the treatment arm ( Table 2) . Post-study therapies were comparable between the treatment groups with the exception of EGFR-targeting agents, which were more commonly administered as post-study anticancer therapy to patients in the FOLFOX-4 arm than in the cetuximab plus FOLFOX-4 arm of the ITT population (23% versus 9% of patients). Small discrepancies were apparent in the biomarker subpopulations ( (53) 70 (45) 86 (54) 49 (51) 44 (54) 47 (51) 39 (54) 21 (36) 42 (55) 2 17 (10) 15 (9) 16 (10) 12 (8) 10 (10) 6 (7) 9 (10) 6 (8) 6 (10)
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Liver metastasis only, n (%) Yes 39 (23) 50 (30) 38 (24) 48 (30) 23 (24) 25 (30) 23 (25) 23 (32) 15 (25) 23 ( (21) 21 (12) 32 (21) 21 (13) 21 (22) 13 (16) 21 (23) 12 (17) 11 (19) 8 (10) Radiotherapy 23 (14) 18 (11) 21 (14) 18 (11) 15 (15) 9 (11) 15 (16) 9 (13) 6 ( Annals of Oncology original article Table 2 . Exposure to study treatment and post-study anticancer therapy in the intention-to-treat and biomarker populations Exposure to treatment
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Biomarker populations KRAS population (n = 315) KRAS wild-type population (n = 179) Relative dose intensity of cetuximab a , n (%) 
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Q1-Q3, interquartile range; 5-FU, 5-fluorouracil; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; FA, folinic acid.
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Annals of Oncology
Patients whose tumors were wild type for KRAS who received cetuximab plus FOLFOX-4 had a 2.6-fold increased odds of response (57% versus 34%; odds ratio 2.551, P = 0.0027) and a 43% reduction in the risk of disease progression (median PFS time 8.3 versus 7.2 months; HR 0.567, P = 0.0064) compared with those who received FOLFOX-4 alone ( Table 3 ). The benefit in relation to these end points was apparent for almost all patient subgroups (Figure 1 ). Survival was also improved by the addition of cetuximab to FOLFOX-4 for patients in this group (Figure 2A and E), but this difference was not statistically significant (median survival time 22.8 versus 18.5 months; HR 0.855, P = 0.39). Conversely, patients whose tumors carried mutations in KRAS who received cetuximab plus FOLFOX-4 had a decreased odds of response (34% versus 53%; odds ratio 0.459, P = 0.0290) and a higher risk of disease progression (median PFS time 5.5 versus 8.6 months; HR 1.720, P = 0.0153) compared with those who received FOLFOX-4 alone. Survival time was also prolonged for patients in this group who received FOLFOX-4 alone, but this difference was not statistically significant (median survival time 17.5 versus 13.4; HR 1.290, P = 0.20, Figure 2B and E).
For patients receiving cetuximab plus FOLFOX-4, survival time was significantly prolonged for those whose tumors were KRAS wild type compared with those whose tumors carried KRAS mutations (Figure 2C and E; median survival time 22.8 versus 13.4 months; HR 0.632, P = 0.013). Conversely, overall survival was similar for those patients receiving FOLFOX-4, regardless of whether their tumors were KRAS wild type or KRAS mutant (Figure 2D and E; median survival time 18.5 versus 17.5 months; HR 0.928, P = 0.70). For patients whose tumors were KRAS wild type, rates of metastatic surgery were significantly higher in those who received cetuximab plus FOLFOX-4 (10/82, 12%) compared with those who received FOLFOX-4 alone (3/97, 3%); CMH test, P = 0.0242; although caution should be exercised in the interpretation of these figures, given the small number of patients involved.
BRAF mutation analysis
BRAF mutations were detected in the tumor tissue of 11 of 309 patients (4%): 6 of whom received cetuximab plus FOLFOX-4 and 5 of whom received FOLFOX-4 alone. All BRAF mutations were detected in tumors that were wild type for KRAS (11/175 samples evaluable for both genes. Of the 11 patients with BRAF mutations, 2 patients, who received cetuximab plus FOLFOX-4, had a partial response to treatment. Efficacy was subsequently analyzed according to the treatment arm for evaluable patients in the KRAS population whose tumors were either wild type or mutant for BRAF. Results for the KRAS wild-type/BRAF wildtype population were very similar to those for the KRAS wildtype population with the addition of cetuximab to FOLFOX-4 associated with significant improvements in response and PFS (Table 3 ). In the small number of patients whose tumors were KRAS wild-type/BRAF mutant (n = 11), overall survival was prolonged in those receiving cetuximab plus FOLFOX-4 compared with FOLFOX-4 alone (median 20.7 versus 4.4 months). This difference should be interpreted cautiously, given the small sample size.
safety
As reported previously, the most common grade 3/4 AE in the safety population was neutropenia, which occurred in 30% of patients receiving cetuximab plus FOLFOX-4 and 34% of those receiving FOLFOX-4 alone ( Table 4 ). The incidence of grade 3/4 cardiac events was higher in patients receiving cetuximab plus FOLFOX-4 (8/170, 5%) compared with those receiving FOLFOX-4 alone (0/168). The safety profile in both treatment arms was comparable for patients with KRAS wild-type and mutant tumors (Table 4) .
discussion
Knowledge of how the specific molecular characteristics of a tumor affect the clinical activity of particular treatment agents will increasingly allow for the tailoring of anticancer therapy on an individual patient basis [19] [20] [21] . This has been exemplified, in the case of mCRC, by the demonstration of the differential efficacy of EGFR-targeting agents according to whether tumors carry mutations in the KRAS gene [5, 10, 11, [22] [23] [24] . Using improved ascertainment approaches, the fraction of OPUS study patients for whom tumor KRAS mutation status could be determined was increased from 69% to 93%. Updated analyses of response and PFS and a new analysis of overall survival according to the treatment group and KRAS tumor mutational status were therefore carried out. Also included was an assessment of the predictive utility of BRAF tumor mutation status in patients with KRAS wild-type disease.
The updated analyses confirmed that tumor KRAS mutation status was predictive for clinical outcome in patients receiving cetuximab plus FOLFOX-4 as first-line treatment for mCRC. In relation to the primary end point, in patients whose tumors were KRAS wild type, the addition of cetuximab to FOLFOX-4 significantly increased the odds of response. Conversely, in patients whose tumors carried mutations in KRAS, the addition of cetuximab to FOLFOX-4 significantly decreased the odds of response. Similarly, the addition of cetuximab to FOLFOX-4 was associated with a significant reduction in the risk of disease progression for patients with KRAS wild-type tumors but a significant increase in the risk of disease progression for patients whose tumors carried KRAS mutations.
In patients with KRAS wild-type tumors, the addition of cetuximab to FOLFOX-4 led to an improvement in median survival time of over 4 months (18.5-22.8 months A randomized phase III study prospectively investigating the EGFR-targeting antibody, panitumumab, in combination with FOLFOX-4 as first-line treatment in patients with KRAS wildtype mCRC reported a significant difference between treatment groups in PFS time, with a HR of 0.80 in favor of patients receiving panitumumab plus FOLFOX-4 compared with FOLFOX-4 alone (P = 0.02) [24] . As in the current study, the converse was true for patients whose tumors carried mutations in KRAS. Overall survival and response rate were also superior for patients with KRAS wild-type disease in the panitumumab plus FOLFOX-4 arm, but the differences did not reach statistical significance. Grade 3/4 skin toxicity was particularly common for patients in this treatment group (36% The primary analysis demonstrated that the addition of cetuximab to chemotherapy conferred no benefit in relation to PFS or overall survival, irrespective of KRAS mutational status, although response rate was significantly improved in patients with KRAS wild-type tumors [25] . Of note, the capecitabine dose was reduced in 19% of patients in the cetuximab arm, from 1000 to 850 mg/m 2 bd due to safety concerns. Before the dose reduction, patients in this arm receiving capecitabine/ oxaliplatin (XELOX) received significantly less capecitabine and oxaliplatin than the corresponding control group (P = 0.001). The lower dose level of capecitabine subsequently administered may also conceivably have been suboptimal for the treatment of mCRC. Indeed, closer inspection of the results suggested that patients with KRAS wild-type tumors who received XELOX plus cetuximab derived no additional benefit, whereas those who received infusional 5-FU/ oxaliplatin (OxMdG) plus cetuximab had prolonged PFS time (HR 0.77, P = 0.056) compared with those receiving OxMdG alone. This effect was more pronounced in patients with tumors wild type for KRAS, BRAF and NRAS (HR 0.72, P = 0.036).
The OPUS study results are consistent with updated data from the Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) study, which demonstrated that the addition of cetuximab to FOLFIRI as first-line therapy for patients with mCRC improved response rate, PFS and overall survival in patients with KRAS wild-type tumors compared with FOLFIRI alone [1] . Both studies are entirely consistent with the revised guidance from regulatory and advisory authorities concerning the administration of cetuximab only to patients with KRAS wild-type mCRC [26] [27] [28] [29] and confirm KRAS tumor mutation status as a powerful predictive biomarker in relation to the clinical efficacy of cetuximab combined with standard first-line chemotherapy. One additional candidate biomarker, BRAF tumor mutation status, was investigated in the current study. As only a small number of tumors with mutations in this gene were identified (11/312), no definitive conclusions concerning possible predictive or prognostic utility can be reached. Analyses of larger numbers of patients will be required to fully explore the biomarker potential of BRAF mutation status in mCRC. Indeed, in the CRYSTAL study, BRAF tumor mutation status was shown to be of prognostic impact for patients receiving FOLFIRI [1] . Similarly, in the phase III CAIRO2 study, BRAF tumor mutation was shown to be a marker of poor prognosis in patients with mCRC receiving capecitabine, oxaliplatin and bevacizumab either with or without cetuximab [30] . Other candidate markers with possible application in this setting include high-level tumor expression of the EGFR ligands amphiregulin and epiregulin [31, 32] , and tumor mutation status of the PIK3CA gene [33] .
In summary, the current study demonstrated that the addition of cetuximab to FOLFOX-4 as first-line therapy for mCRC improved clinical outcome compared with FOLFOX-4 alone in patients whose tumors were wild type for KRAS and confirmed KRAS tumor mutation status as a clinically useful predictive factor for the efficacy of cetuximab plus FOLFOX-4 in relation to response and PFS. 
